You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Parnell Pharmaceuticals delisting from Nasdaq
South Korean Multichannel Industry To Survive With Right Strategies
South Korean Telcos Drive Next Wave Of Growth Through Home IoT Opportunities
Mining Exploration Insights: Financing Falls To 8-Month Low In October
Taking Advantage of Issuance Trends in 2020
Australia-based Parnell Pharmaceuticals Holdings Ltd. will delist from the Nasdaq, effective Dec. 31.
The company said it believes that there has been an incongruence between the potential realizable value of Parnell's underlying assets and its share price as a Nasdaq-listed company, according to a news release.
The veterinarian pharmaceutical company anticipates its shares to be quoted on the OTC Pink open market following the delisting.